HuMark® Biomarker Discovery Services

HuMark™ Biomarker Discovery Service provides  pre-clinical research programs more predictive power of actual patient outcomes. The reasons for the failure of targeted oncology drugs is quite varied and often not well known. Even when the receptor responsible for signaling for the particular tumor is known, a drug that targets this receptor usually is not capable of producing significant responses in most tumors, e.g., EGFR inhibitors ineffective in presence of KRAS mutation, or activation of the PI3K pathway to overcome EGFR blockade.

Biomarkers are defined as any biological measurement that provides actionable information regarding disease progression, pharmacology or safety that can be used as a basis for decision making in drug development. They can serve as a molecular indication of drug efficacy or toxicity. CrownBio’s biomarker expression services enable a detailed understanding of molecular mechanisms for drug susceptibility and resistance.

Effective identification and deployment of biomarkers is essential to achieving a new era of predictive, preventive and personalized medicine. HuMark™ Biomarker Service  promise to accelerate basic and translational research, focus therapeutic indication and speed “go-no-go” decision in the early stages of preclinical development.

CrownBio's Biomarker Services allow you to:

• Assess after one or two treatments if a patient's tumor is responding to treatment
• Determine more definitively if a tumor is dying, even if it is not shrinking
• Identify which cancer patients are at high risk of their tumor coming back after therapy
• Determine if a patient's tumor is likely to respond at all to a specific treatment
• Efficiently evaluate whether an investigational therapy is effective for tumor treatment

System Biology